An ongoing global multicenter phase III study compared sunvozertinib with platinum-containing chemotherapy as the first-line treatment for EGFR ex20ins mutations NSCLC (WU-KONG28) to confirm its excellent efficacy. Here, EGFR is linked to non-small cell lung carcinoma.